慢病毒载体平台：产品/疗法研究证据

慢病毒载体平台：相关研究证据

2 条相关资料

In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells.

PubMed 2026/08/10 发表Mol TherQ1 · IF 11.4（JCR 2025）

Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector.

PubMed 2025/07/16 发表Mol TherQ1 · IF 11.4（JCR 2025）